机构：[1]Department of Laboratory, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan Province, China
Abstract:
Objective: This study aimed to assess the effectiveness of Molnupiravir and Lianhua Qingwen in treating patients with
novel coronavirus pneumonia (COVID-19).
Materials and Methods: We conducted a study involving 14 cases of COVID-19 infection within a unit group in Laos.
During the treatment regimen, these patients received the antiviral drugs Molnupiravir and Lianhua Qingwen as prescribed.
We utilized laboratory results of viral nucleic acid tests as observational parameters and statistically analyzed the data using
SPSS 26.0 software (linear regression analysis). Our data analysis aimed to determine if there were significant differences
in the Ct values of the N gene and ORF1ab gene of SARS-CoV-2 before and after treatment.
Results: The results indicated statistically significant differences in the N gene (t =﹣7.014, P < 0.001) and ORF1ab gene
(t =﹣7.398, P < 0.001). Post-treatment, the values of the N gene and ORF1ab gene were significantly higher than their
pre-treatment values, signifying that the combined utilization of Molnupiravir and Lianhua Qingwen had a substantial
impact on the treatment of COVID-19.
Conclusion: Molnupiravir and Lianhua Qingwen effectively inhibited the replication of SARS-CoV-2, resulting in a
marked improvement in the clinical symptoms of the patients. Laboratory test results also indicated a significant reduction
in viral load. These findings provide substantial evidence supporting the efficacy of the combination of Molnupiravir and
Lianhua Qingwen in the treatment of COVID-19.
基金：
The Yunnan Provincial Department of Science and Technology and Kunming Medical University’s Joint Special Funding for Applied Basic Research(202101AY070001-250)
语种：
外文
第一作者：
第一作者机构：[1]Department of Laboratory, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan Province, China
通讯作者：
通讯机构：[1]Department of Laboratory, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan Province, China
推荐引用方式(GB/T 7714)：
Min Tang,Na Li,Jinhua Dao,et al.Combination of Chinese and Western Medicine: Molnupiravir and Lianhua Qingwen in the Treatment of Novel Coronavirus Pneumonia (COVID-19)[J].International Journal of Clinical Case Reports and Reviews.2024,16(5):doi:10.31579/2690-4861/417.
APA：
Min Tang,Na Li,Jinhua Dao,Jianqiong Wang,Rui Tao&Ning Xu.(2024).Combination of Chinese and Western Medicine: Molnupiravir and Lianhua Qingwen in the Treatment of Novel Coronavirus Pneumonia (COVID-19).International Journal of Clinical Case Reports and Reviews,16,(5)
MLA：
Min Tang,et al."Combination of Chinese and Western Medicine: Molnupiravir and Lianhua Qingwen in the Treatment of Novel Coronavirus Pneumonia (COVID-19)".International Journal of Clinical Case Reports and Reviews 16..5(2024)
